Switching cannabinoid response from CB(2) agonists to FAAH inhibitors

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Immunology

Background:

• The endocannabinoid system plays a role in inflammation.
• Cannabinoid receptor 2 (CB2) agonists and fatty acid amide hydrolase (FAAH) inhibitors are therapeutic targets.
• Isoxazole derivatives have been explored for various biological activities.

Purpose of the Study:

• To design and synthesize 3-carboxamido-5-aryl-isoxazoles.
• To evaluate these compounds as CB2 agonists and FAAH inhibitors.
• To assess the anti-inflammatory potential of selected compounds in a colitis model.

Main Methods:

• Synthesis of 3-carboxamido-5-aryl-isoxazole library.
• Pharmacological evaluation for CB2 receptor agonism and FAAH inhibition.
• In vivo assessment using a DSS-induced acute colitis mouse model.

Main Results:

• Structure-activity relationships were established, allowing modulation of activity from CB2 agonism to FAAH inhibition.
• Compounds 10 and 11 demonstrated significant FAAH inhibitory activity.
• Compounds 10 and 11 effectively inhibited the development of DSS-induced acute colitis in mice.

Conclusions:

• Novel isoxazole derivatives can be designed to target either CB2 receptors or FAAH.
• Compounds 10 and 11 show promise as anti-inflammatory agents.
• These compounds represent potential lead candidates for the development of new drugs for inflammatory bowel disease (IBD).